The FDA has approved a new agent for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established ASCVD as an adjunct to diet and maximally tolerated statin therapy.
The FDA has approved a new agent for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established ASCVD as an adjunct to diet and maximally tolerated statin therapy.
The FDA has approved a new agent for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established ASCVD as an adjunct to diet and maximally tolerated statin therapy.
The US Food and Drug Administration has approved the first drug for the treatment of allergic reactions that could occur with accidental exposure to peanuts in children.
In an interview with Gastroenterology Consultant, Mark Gromski, MD, discussed the importance of the FDA’s recent clearance of the first disposable duodenoscope and how the clearance can impact clinical...
FDA has strengthened an existing warning of constipation associated with the use of clozapine, stating that this constipation can, uncommonly, progress to serious bowel complications, including blockage of...
